News >

NICE Recommends Against Frontline Pembrolizumab/Axitinib in Advanced RCC

Kristi Rosa
Published: Wednesday, Feb 12, 2020

The United Kingdom’s National Institute for Health and Care Excellence (NICE) has chosen to not recommend the combination of pembrolizumab (Keytruda) and axitinib (Inlyta) for use in treatment-naïve adult patients with advanced renal cell carcinoma (RCC).1

“Overall, an option that improved survival and reduced [AEs] would be welcomed by patients and clinicians to allow more choice of treatment and individualized care plans,” the committee concluded.


  1. Appraisal consultation document: pembrolizumab with axitinib for untreated advanced renal cell carcinoma. National Institute for Health and Care Excellence. Published February 2020. Accessed February 12, 2020.           
  2. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116-1127. doi: 10.1056/NEJMoa1816714.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication